Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Clinical Stage I Gastric Cancer AJCC v8 2Vulvar Neoplasms 1Urinary Bladder Neoplasms 1Prostate Adenocarcinoma 1Postoperative Complications 1Neoplasms 1Lymphedema 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

luprolide acetate gel depot 3Magnetic Resonance Spectroscopy 3Specimen Handling 2Leuprolide 2Goserelin 2Biopsy 2relugolix 1radium Ra 223 dichloride 1niraparib 1gallium 68 PSMA-11 1fluciclovine F-18 1flibanserin 1enzalutamide 1atezolizumab 1apalutamide 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abiraterone 1X-Rays 1Triptorelin Pamoate 1Radium-223 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiosurgery 1Radiation 1Prednisone 1PROSTVAC 1Methods 1Lymph Node Excision 1Glutamate Carboxypeptidase II 1Estramustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Prostate Adenocarcinoma × Lymph Node Excision × Clear all
NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Washington

Phase 2 Recruiting
100 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡